ATAI

ATA Inc-China (ATAI) | Rumor.io

ATA Inc-China

ATAI

Attention (50-day avg)0%

Attention rank (50-day avg)#900

Bullish sentiment (50-day avg)77%

Price to earnings ratio-0.29

Market capitalization315.2M

Earnings per share-2.79

Dividend yield (TTM)—

Revenue (annual)4.1M

Net income (annual)-660.1M

Social

What share of all stock conversation is about ATAI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0.01% -0.01

Sep 15

ATAI Life Sciences has been delisted, according to a recent comment.
CVRs (common stock equivalents) for ATAI are reportedly worthless and non-tradable.
The merger event has led to some investors expressing dissatisfaction and frustration.

Generated by AI

Sentiment

Of the messages about ATAI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +37.5	72.13% -0.37	79.61% -10.6
Bearish	—	0% -37.5	27.87% +0.37	20.39% +10.6

Bullish· Jul 16

The company has a clean balance sheet with zero debt and a significant cash position, which could warrant a massive premium on a buyout.
The company's pipeline, including its ibogaine program and non-hallucination development program, could produce $4 billion annually and more in the future, creating a significant opportunity for growth.
A buyout of the company could be at a price of at least $12 per share, which would be a significant return on investment for current holders.

Bearish· Jul 16

The company's valuation is questioned, with some suggesting it's selling itself "cheap" at a price of $3.1 billion.
The overnight price drop is seen as a sign of "garbage" being up, with some users expressing surprise at the low price and others celebrating the supposed victory of shorts.
The company's potential sale is met with skepticism, with some users doubting that Lily will pay "top dollar" for the company, and others questioning the valuation based on the company's market capitalization.

Generated by AI

Topics

Of the messages about ATAI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	90.19%	10.5%
Technical Analysis	100%	100%	4.6%	28.11%
Analysts	0%	0%	1.74%	29.45%
Macro	0%	0%	1.74%	31.66%
Earnings	0%	0%	1.74%	0.26%
Controversies	0%	0%	0%	0.02%

Analysts· Jul 13

Analysts have initiated coverage on ATAI Life Sciences with various ratings and price targets, including Buy, Outperform, and Overweight.
Price targets for ATAI Life Sciences range from $19 to $45, with analysts from firms such as Cowen, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald making recommendations.
ATAI Life Sciences has received Buy ratings and price targets from analysts at firms including Aegis Capital, Citigroup, and Berenberg Bank, among others.

Announcements· Jul 16

Eli Lilly is reportedly in talks to acquire psychedelic drug developer Atai Life Sciences N.V. (ATAI) at a premium, with a potential deal announcement as soon as this week.
The acquisition would strengthen Lilly's neuroscience pipeline and reinforce growing interest from large pharma in next-generation mental health treatments, with the psychedelic treatment market estimated to reach $7B by 2032.
A formal merger agreement filed on EDGAR by Friday morning is seen as a key indicator of the deal's progress, with any absence of such a filing suggesting that negotiations may have paused due to another suitor entering the room.

Technical Analysis· Jul 1

ATAI Life Sciences has seen a significant pre-market volume increase following positive data reaction, with a weekly bull flag needing a price of $2.64 to confirm.
The company's stock has broken past its April 2024 high of $2.85, with some analysts predicting continued momentum and potential support at $2.7.
ATAI's chart setup is comparable to that of $BMNR, with indicators and technical analysis suggesting a possible breakout and potential gains ahead.

Generated by AI

Community

Of the messages about ATAI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	97.5%	50.39%	41.58%
Newcomers	0%	2.5%	49.61%	58.42%

Regulars· Jul 30

The Lilly-ATAI merger proxy has been dropped, outlining the terms of the deal, including cash and contingent value rights (CVRs) for shareholders.
Regular investors are discussing the implications of the Lilly-ATAI deal, with some speculating that the deal may be a result of ATAI's desperation or Lilly's perception of a commercial advantage in ATAI's short-acting approach.
Some investors are voting against the merger, citing concerns over the terms and the potential for further bidders or a significant improvement in the bid.

Newcomers· Sep 14

New investors are learning about the delisting of ATAI due to the acquisition by Eli Lilly, and are unsure about how to recover their returns.
Some owners are receiving cash payouts from the delisting, while others are waiting for CRV (contingent value rights) to be settled.
The takeover has led to a shift of funds to Ocugen (OCGN), with investors hoping the new company will not follow the same path as ATAI.

Generated by AI

Also Discussed

Investors talking about ATAI also mention

#	Name	Attention
1	Compass Pathways plc - ADRCMPS	0.06%+0.05
2	Cybin Inc.CYBN	0.01%+0
3	GH Research PLCGHRS	0%0
4	Definium Therapeutics, Inc.MNMD	0%+0
5	AdvisorShares Psychedelics ETFPSIL	0.02%+0.01
6	Bright Minds Biosciences Inc.DRUG	0%new
7	GBNH - Greenbrook TMS Inc.	——
8	Alto Neuroscience Inc.ANRO	0%new
9	SEEL - Seelos Therapeutics, Inc.	——
10	Silo Pharma Inc.SILO	0%new

ATA Inc-China

Healthcare
Biotechnology

AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on developing mental health treatments. The company concentrates on rapid-acting, durable, and convenient therapies designed to address difficult-to-treat psychiatric conditions, including depression, treatment-resistant depression, social anxiety disorder, and other central nervous system disorders. Its current pipeline includes investigational programs based on psychedelic-inspired and neuroplasticity-driven compounds, developed through internal research and strategic collaborations. AtaiBeckley Inc. also works across discovery, clinical development, and potential commercialization activities, reflecting its role in advancing new therapeutic options within the mental health and neuroscience markets. Headquartered in New York, AtaiBeckley Inc. operates as part of the broader biotechnology and pharmaceutical sector, where it is known for targeting unmet needs in mental health care with a specialized, research-focused portfolio.

Website

Location

250 West 34th Street

New York, NY, 10119

United States

Social

What share of all stock conversation is about ATAI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0.01% -0.01

Sep 15

ATAI Life Sciences has been delisted, according to a recent comment.
CVRs (common stock equivalents) for ATAI are reportedly worthless and non-tradable.
The merger event has led to some investors expressing dissatisfaction and frustration.

Generated by AI

Sentiment

Of the messages about ATAI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +37.5	72.13% -0.37	79.61% -10.6
Bearish	—	0% -37.5	27.87% +0.37	20.39% +10.6

Bullish· Jul 16

The company has a clean balance sheet with zero debt and a significant cash position, which could warrant a massive premium on a buyout.
The company's pipeline, including its ibogaine program and non-hallucination development program, could produce $4 billion annually and more in the future, creating a significant opportunity for growth.
A buyout of the company could be at a price of at least $12 per share, which would be a significant return on investment for current holders.

Bearish· Jul 16

The company's valuation is questioned, with some suggesting it's selling itself "cheap" at a price of $3.1 billion.
The overnight price drop is seen as a sign of "garbage" being up, with some users expressing surprise at the low price and others celebrating the supposed victory of shorts.
The company's potential sale is met with skepticism, with some users doubting that Lily will pay "top dollar" for the company, and others questioning the valuation based on the company's market capitalization.

Generated by AI

Topics

Of the messages about ATAI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	90.19%	10.5%
Technical Analysis	100%	100%	4.6%	28.11%
Analysts	0%	0%	1.74%	29.45%
Macro	0%	0%	1.74%	31.66%
Earnings	0%	0%	1.74%	0.26%
Controversies	0%	0%	0%	0.02%

Analysts· Jul 13

Analysts have initiated coverage on ATAI Life Sciences with various ratings and price targets, including Buy, Outperform, and Overweight.
Price targets for ATAI Life Sciences range from $19 to $45, with analysts from firms such as Cowen, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald making recommendations.
ATAI Life Sciences has received Buy ratings and price targets from analysts at firms including Aegis Capital, Citigroup, and Berenberg Bank, among others.

Announcements· Jul 16

Eli Lilly is reportedly in talks to acquire psychedelic drug developer Atai Life Sciences N.V. (ATAI) at a premium, with a potential deal announcement as soon as this week.
The acquisition would strengthen Lilly's neuroscience pipeline and reinforce growing interest from large pharma in next-generation mental health treatments, with the psychedelic treatment market estimated to reach $7B by 2032.
A formal merger agreement filed on EDGAR by Friday morning is seen as a key indicator of the deal's progress, with any absence of such a filing suggesting that negotiations may have paused due to another suitor entering the room.

Technical Analysis· Jul 1

ATAI Life Sciences has seen a significant pre-market volume increase following positive data reaction, with a weekly bull flag needing a price of $2.64 to confirm.
The company's stock has broken past its April 2024 high of $2.85, with some analysts predicting continued momentum and potential support at $2.7.
ATAI's chart setup is comparable to that of $BMNR, with indicators and technical analysis suggesting a possible breakout and potential gains ahead.

Generated by AI

Community

Of the messages about ATAI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	97.5%	50.39%	41.58%
Newcomers	0%	2.5%	49.61%	58.42%

Regulars· Jul 30

The Lilly-ATAI merger proxy has been dropped, outlining the terms of the deal, including cash and contingent value rights (CVRs) for shareholders.
Regular investors are discussing the implications of the Lilly-ATAI deal, with some speculating that the deal may be a result of ATAI's desperation or Lilly's perception of a commercial advantage in ATAI's short-acting approach.
Some investors are voting against the merger, citing concerns over the terms and the potential for further bidders or a significant improvement in the bid.

Newcomers· Sep 14

New investors are learning about the delisting of ATAI due to the acquisition by Eli Lilly, and are unsure about how to recover their returns.
Some owners are receiving cash payouts from the delisting, while others are waiting for CRV (contingent value rights) to be settled.
The takeover has led to a shift of funds to Ocugen (OCGN), with investors hoping the new company will not follow the same path as ATAI.

Generated by AI

ATA Inc-China

Social

Sep 15

Sentiment

Bullish· Jul 16

Bearish· Jul 16

Topics

Analysts· Jul 13

Announcements· Jul 16

Technical Analysis· Jul 1

Community

Regulars· Jul 30

Newcomers· Sep 14

Also Discussed

ATA Inc-China

Company Information

Location

Also Discussed

Social

Sep 15

Sentiment

Bullish· Jul 16

Bearish· Jul 16

Topics

Analysts· Jul 13

Announcements· Jul 16

Technical Analysis· Jul 1

Community

Regulars· Jul 30

Newcomers· Sep 14